In my opinion, Denner knows that this little "Investor Day" stunt would crater the stock price further. Get the rest of the institutional shareholders to sell because they don't want to be left holding a barely-liquid stock. Thus prompting more selling pressure and a lower SP.
If Sarissa and/or Amarin do not start buying at some point, then I really don't know WTF is going on. But if they really think that any of what they have been doing was "helpful" then they are mismanaging at best. As it is, they are a virtual generic pharma company with almost no sales and marketing effort. Just not really sure what their real plan is. Because if their plan is to expand acceptance of Vascepa/Vazkepa, and just grow the "franchise", then are doing one hell of a shitty job.
Market Data 
Markets 
AI
